Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV
Clinical Infectious Diseases · 15.10.2024 · 79 (4) · 978-982
DOI: 10.1093/cid/ciae151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.03.2024. Verfasst von Quynh Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California San Diego, California, USA. Hauptthemen laut MEDLINE: Weight Loss, HIV Infections, Body Mass Index, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Weight gain and associated metabolic complications are increasingly prevalent among people with human immunodeficiency virus (PWH). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are incretin-based therapies for diabetes and weight management that have been shown to result in substantial weight loss; however, studies of their effects in PWH are limited.
Methods
A retrospective single-center cohort study was conducted among PWH who were taking GLP-1RAs at the University of California, San Diego Owen Clinic between 1 February 2021 and 1 February 2023. Baseline clinical data were collected and changes in weight, body mass index (BMI), and hemoglobin A1C (A1C) before starting GLP-1RAs compared to the most recent clinic visit were calculated (with a minimum of 3 months follow-up time required). Logistic regression was performed to identify variables associated with >5% of total body weight loss.
Results
A total of 225 patients received on average 13 months of GLP-1RA therapy, with 85 (37.8%) achieving the maximum GLP-1RA dose. GLP-1RA therapy resulted, on average, in a weight loss of 5.4 kg, decrease in BMI by 1.8 kg/m2, and decrease in A1C by 0.6%. In the multivariable analysis, higher baseline BMI (odds ratio [OR], 1.10 [95% confidence interval {CI}, 1.03–1.16]), treatment duration of GLP-1RA therapy >6 months (OR, 3.12 [95% CI, 1.49–6.49]), and use of tirzepatide (OR, 5.46 [95% CI, 1.44–20.76]) were significantly more likely to be associated with >5% weight loss.
Conclusions
Use of GLP-1RAs led to declines in weight, BMI, and A1C among PWH and offers an additional strategy to address weight gain and diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of California San Diego, California, USA.
- Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, California, USA.
- Department of Medicine, University of California San Diego, California, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
ORCID-Profile: Quynh Nguyen, Darcy Wooten
Zitieren
APA
Nguyen, Q., Wooten, D., Lee, D., Moreno, M., Promer, K., Rajagopal, A., Tan, M., Tang, M., Duren, K., Yin, J., & Hill, L. (2024). Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Clinical Infectious Diseases, 79(4), 978-982. https://doi.org/10.1093/cid/ciae151
Vancouver
Nguyen Q, Wooten D, Lee D, Moreno M, Promer K, Rajagopal A, et al. Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Clinical Infectious Diseases. 2024;79(4):978-982. doi:10.1093/cid/ciae151
BibTeX
@article{Nguyen2024,
author = {Nguyen, Quynh and Wooten, Darcy and Lee, Daniel and Moreno, Manuel and Promer, Katherine and Rajagopal, Amutha and Tan, Matthew and Tang, Michael and Duren, Kye and Yin, Jeffrey and Hill, Lucas},
title = {Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {79},
number = {4},
pages = {978--982},
doi = {10.1093/cid/ciae151}
}
EUVIMED